Literature DB >> 18407765

Antibody-cytokine fusion proteins: applications in cancer therapy.

Elizabeth Ortiz-Sánchez1, Gustavo Helguera, Tracy R Daniels, Manuel L Penichet.   

Abstract

BACKGROUND: Antibody-cytokine fusion proteins consist of cytokines fused to an antibody to improve antibody-targeted cancer immunotherapy. These molecules have the capacity to enhance the tumoricidal activity of the antibodies and/or activate a secondary antitumor immune response.
OBJECTIVE: To review the strategies used to develop antibody-cytokine fusion proteins and their in vitro and in vivo properties, including preclinical and clinical studies focusing on IL-2, IL-12 and GM-CSF.
METHODS: Articles were found by searching databases such as PubMed and Clinical Trials of the US National Institutes of Health. RESULTS/
CONCLUSION: Multiple antibody-cytokine fusion proteins have demonstrated significant antitumor activity as direct therapeutics or as adjuvants of cancer vaccines in preclinical studies, paving the way for their clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407765      PMCID: PMC4535341          DOI: 10.1517/14712598.8.5.609

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  169 in total

Review 1.  Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy.

Authors:  G Helguera; S L Morrison; M L Penichet
Journal:  Clin Immunol       Date:  2002-12       Impact factor: 3.969

2.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Authors:  J P Leonard; M L Sherman; G L Fisher; L J Buchanan; G Larsen; M B Atkins; J A Sosman; J P Dutcher; N J Vogelzang; J L Ryan
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

Review 3.  Antibody engineering for therapeutics.

Authors:  Leonard Presta
Journal:  Curr Opin Struct Biol       Date:  2003-08       Impact factor: 6.809

4.  The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

Authors:  M Imboden; K R Murphy; A L Rakhmilevich; Z C Neal; R Xiang; R A Reisfeld; S D Gillies; P M Sondel
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.

Authors:  Gustavo Helguera; José A Rodríguez; Manuel L Penichet
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

6.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

7.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Authors:  Barbara Carnemolla; Laura Borsi; Enrica Balza; Patrizia Castellani; Raffaella Meazza; Alexander Berndt; Silvano Ferrini; Hartwig Kosmehl; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

8.  An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

Authors:  Stephen D Gillies; Yan Lan; Steven Williams; Frank Carr; Stephen Forman; Andrew Raubitschek; Kin-Ming Lo
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

View more
  15 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.

Authors:  Rosendo Luria-Pérez; Pierre V Candelaria; Tracy R Daniels-Wells; José A Rodríguez; Gustavo Helguera; Manuel L Penichet
Journal:  Cytokine       Date:  2019-05-20       Impact factor: 3.861

3.  89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.

Authors:  Kirstin A Zettlitz; Felix B Salazar; Reiko E Yamada; K Ryan Trinh; Alex Vasuthasawat; John M Timmerman; Sherie L Morrison; Anna M Wu
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

Review 4.  Synthetic biology in mammalian cells: next generation research tools and therapeutics.

Authors:  Florian Lienert; Jason J Lohmueller; Abhishek Garg; Pamela A Silver
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01-17       Impact factor: 94.444

5.  Spaceflight effects on T lymphocyte distribution, function and gene expression.

Authors:  Daila S Gridley; James M Slater; Xian Luo-Owen; Asma Rizvi; Stephen K Chapes; Louis S Stodieck; Virginia L Ferguson; Michael J Pecaut
Journal:  J Appl Physiol (1985)       Date:  2008-11-06

6.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

Review 7.  Immunostimulatory biomaterials to boost tumor immunogenicity.

Authors:  Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel
Journal:  Biomater Sci       Date:  2020-09-02       Impact factor: 6.843

Review 8.  AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.

Authors:  E Jensen-Jarolim; H J Bax; R Bianchini; S Crescioli; T R Daniels-Wells; D Dombrowicz; E Fiebiger; H J Gould; S Irshad; J Janda; D H Josephs; F Levi-Schaffer; L O'Mahony; G Pellizzari; M L Penichet; F Redegeld; F Roth-Walter; J Singer; E Untersmayr; L Vangelista; S N Karagiannis
Journal:  Allergy       Date:  2017-10-05       Impact factor: 13.146

9.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

10.  Cancer vaccine development: designing tumor cells for greater immunogenicity.

Authors:  Erica N Bozeman; Rangaiah Shashidharamurthy; Simon A Paulos; Ravi Palaniappan; Martin D'Souza; Periasamy Selvaraj
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.